Alvotech Announces $91.2 Million Public Offering and $66.85 Million Private Placement

Alvotech filed a Form 6-K on June 16, 2026, announcing a dual capital raising transaction. The company entered into an underwriting agreement for a public offering of 22,666,667 ordinary shares at $3.75 per share, with an additional 3,400,000 shares option that was fully exercised, generating approximately $91.20 million in net proceeds. Concurrently, Alvotech entered into subscription agreements for a private placement of 17,826,666 ordinary shares at the same price, expected to raise approximately $66.85 million. The offering is expected to close on June 17, 2026, while the private placement will close within seven business days thereafter. The filing also includes a supplemental risk factor disclosing that the company received Complete Response Letters from the FDA for its Biologics License Applications for AVT03, AVT05, and AVT06 following manufacturing facility deficiencies identified during a July 2025 inspection. Alvotech resubmitted BLAs for AVT05 and AVT06 on June 4, 2026, but FDA approval remains uncertain pending potential re-inspection of the Reykjavik facility.